GW Pharma dient een aanvraag tot wijziging van type II in voor Epidyolex in Europa


De Beste Kwaliteit CBD Olie?

MHBioShop CBD Olie Specialist  

Pour la meilleure qualité d’Huile de CBD Visitez specialiste Huile de CBD


GW Pharmaceuticals (NASDAQ:GWPH) submits Type II Variation Application to the European Medicines Agency (EMA) seeking approval of EPIDYOLEX, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic condition and a leading cause of genetic epilepsy.

If approved, this will be the third licensed indication for GW’s cannabidiol oral solution in Europe.

Click to subscribe to real-time analytics on GWPH

Now read: Applied Therapeutics EPS misses by $0.59 »

Lees Meer

Leave a Comment